Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU) | Synapse
December 6, 2025Open Access
Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU)
Puntos clave
Radiotherapy combined with nivolumab and ipilimumab shows promise for advanced esophageal cancer treatment.
Primary endpoint focuses on assessing treatment efficacy in adult patients with recurrent esophageal cancer.
Randomized controlled trial protocol registered under Japan Clinical Oncology Group study JCOG2311.
Support for exploring innovative therapies may enable improved outcomes in esophageal cancer patients.
Resumen
This trial has been registered on November 5th, 2024, in the Japan Registry of Clinical Trials as jRCT1031240461 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT1031240461).